In TrendsStock MarketRBI MPC Meeting LIVERBI Repo Rate NewsNifty OutlookGold and Silver PricesAsian StocksPM-KISANAI companies run virtual drug trials, aim to improve success of human studiesAI firms are using virtual patients and simulated clinical trials to assess experimental drugs before costly human studies, with some models claiming to predict trial outcomes. Pharma companies see potential in the technology but say human trials remain essential.By Reuters October 7, 2026, 4:08:02 PM IST (Published)Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company’s CEO predicting annual peak sales of $5 billion. When a late-stage trial missed its goal last month, shares fell 11%, erasing $30 billion in market value.AI start-up BioinvestGPT was not surprised. In July, it ran a simulated trial to measure how virtual patients would respond to del-desiran and predicted an insignificant clinical benefit.It and other artificial intelligence companies say they are working with some drugmakers on virtual trials to boost the odds an experimental medicine will prove safe and effective when used by actual patients in an expensive traditional clinical trial.The global biopharmaceutical industry spends some $140 billion a year on human clinical testing, but only around 12% of…
Original source: https://www.cnbctv18.com/technology/
